Existing Data Sources for Clinical Epidemiology: The PHARMO Database Network

J. G. Kuiper, M. Bakker, F. J. A. Penning-van Beest, R. M. C. Herings

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The PHARMO Database Network provides a unique opportunity to gain insight in the complete patient journey and healthcare in the Netherlands. The PHARMO Database Network is a population-based network of electronic healthcare databases and combines anonymous data from different primary and secondary healthcare settings in the Netherlands. Healthcare settings include general practitioners, out-patient and in-patient pharmacies, hospitals and clinical laboratories. Furthermore, databases are linked with external registries such as the Cancer Registry, Pathology Registry and Perinatal Registry. The different data sources are linked on a patient level through probabilistic linkage based on validated algorithms. The longitudinal and ongoing nature of the PHARMO Database Network system enables to follow up more than 10 million residents of the Netherlands for an average of 12 years. Data collection period, catchment area and overlap between data sources differ. Access to the PHARMO Database Network is, by governance regulations of the data collection, restricted to researchers of the PHARMO Institute and academic affiliates. Each data request is checked against privacy and company policies, and requires approval of the privacy and governance board. The terms and conditions and a data application form are available on the PHARMO website (www.pharmo.com).
Original languageEnglish
Pages (from-to)415-422
Number of pages8
JournalClinical Epidemiology
Volume12
DOIs
Publication statusPublished - 2020

Keywords

  • Netherlands database electronic health record observational research pharmacoepidemiology record linkage Research. This independent research institute performs financially supported studies for government and related healthcare authorities and several pharmaceutical companies. As this paper uses data from existing publications without any direct enrolment of subjects, ethical approval or informed consent is not necessary according to the Dutch law regarding medical research involving human subjects (WMO), which is enforced by the Central Committee on Research involving Human Subjects (Centrale Commissie Mensgebonden Onderzoek [CCMO]). The authors report no other conflicts of interest in this work.

Cite this